1. Васюк Ю.А., Садулаева И.А., Ющук Е.Н. и др. Ингибиторы ренина - новое направление в лечении артериальной гипертонии // Тер. архив. - 2010. - № 9. - С. 53-59.
2. Доклад ВОЗ о глобальной ситуации по проблемам НИЗ. Анализ глобального бремени неинфекционных болезней, их факторов риска и детерминантов. - Женева: ВОЗ, 2011. - 176 с.
3. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр) // Системные гипертензии. - 2010. - № 3. - С. 5-26.
4. Мухин Н.А., Фомин В.В. Ренин - мишень прямой фармакологической блокады при артериальной гипертонии // Тер. архив. - 2009. - № 8. - С. 5-9.
5. Фуштей И.М., С.Л. Подсевахина, А.И. Паламарчук и др. Влияние антигипертензивной терапии на функциональное состояние почек, показатели метаболического статуса и активность воспаления у больных с гипертензивной нефропатией // Вестник неотложной и восстановительной медицины. - 2013. - Т. 14, № 1. - С. 63-67.
6. Чазова И.Е., Фомин В.В., Пальцева Е.М. Прямой ингибитор ренина алискиренновые возможности защиты почек при артериальной гипертензии // Клиническая нефрология. - 2009. - № 1 - С. 44-49.
7. Andersen K., Weinberger M.H., Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial // Hypertension. - 2008. - Vol. 26. - P. 589-599.
8. Azizi M., Webb R., Nussberger J. et al. Renin inhibition with aliskiren: where are we now, and where are we going? // J. Hypertens. - 2006. - Vol. 24. - P. 243-256.
9. Brown M., McInnes G., Papst C. et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial // Lancet. - 2011. - Vol. 377. - P. 312-320.
10. Choi D.E., Jeong J.Y., Lim B.J. et al. Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice // J. Urol. - 2011. - Vol. 186. - P. 694-701.
11. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2013. - Vol. 31. - P. 1281-1357.
12. Danser A.H.J., Deinum J. Renin, prorenin and the putative prorenin receptor // Hypertension. - 2005. - Vol. 46. - P. 1069-1076.
13. Daugherty K.K. Aliskiren // Am. J. Health Syst. Pharm. - 2008. -Vol. 65, No. 14. - P. 1323-1332.
14. Fisher N.D., Jan Danser A.H., Nussberger J. et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy human // Circulation. - 2008. - Vol. 117. - No. 25. -P. 3199-3205.
15. Gheorghiade M., Bohm M., Greene S.J. et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial // JAMA. - 2013. - Vol. 309. - P. 1125-1135.
16. Fukutomi M., Hoshide S., Mizuno H. et al. Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients // Am. J. Hypertens. - 2014. - Vol. 27, No. 1. - P. 14-20.
17. Gilbert C.J., Gomes T., Mamdani M.M. et al. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers // Can. J. Cardiol. - 2013. - Vol. 29. - No. 5. -P. 586-591.
18. Gradman A.H., Schmieder R.E., Lins R.L. et al. Aliskiren, a novel, orally-effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients // Circulation. - 2005. -Vol. 111. - P. 1012-1018.
19. Jordan J., Engeli S., Boye S.W. Direct renin inhibition with aliskiren in obese patients with arterial hypertension // Hypertension. - 2007. - Vol. 49, No. 5. - P. 1047-1055.
20. Imanishi T., Tsujioka H., Ikejima H. et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes // Hypertension. - 2008. -Vol. 52. - P. 563-557.
21. Kario K., Pickering T.G., Umeda Y. et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective study // Circulation. - 2003. - Vol. 107. - P. 1401-1406.
22. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases // Pharmacol. Rev. - 2000. - Vol. 52, No. 5. - Р. 11-34.
23. Liu Y., Yan R., Song A. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy // Am. J. Hypertens. - 2014. - Vol. 27, No. 2. - P. 268-278.
24. Mende C.W. Application of direct renin inhibition to chronic kidney disease // Cardiovasc. Drugs Ther. - 2010. - Vol. 14. -P. 130-149.
25. Mihai G., Varghese J., Kampfrath T. et al. Aliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial [Электронный ресурс] // J. Am. Heart Assoc. - 2013. - Vol. 2, No. 3. - doi: 10.1161/JAHA.112.004879.
26. McMurray J., Pitt B., Latini R. et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure // Circ. Heart Fail. - 2008. - Vol. 1. - P. 17-24.
27. Ogawa M., Suzuki J., Takayama K. et al. Impaired post-infarction cardiac remodeling in chronic kidney disease is due to excessive renin release // Lab. Invest. - 2012. - Vol. 92, No. 12. - P. 1766-1776.
28. Oh B.-H., Mitchell J., Herron J.R. et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension // Am. Coll. Cardiol. - 2007. - Vol. 49. - P. 1157-1163.
29. Ohshawa M., Tamura K., Kanaoka T. et al. Addition of aliskiren to angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease // Int. Mol. Sci. - 2013. - Vol. 14. - P. 15361-15375.
30. Oparil S., Yarows S.A., Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial // Lancet. - 2007. - Vol. 370. - P. 221-229.
31. Parving H.-H., Brenner B.M., McMurray J.J.V. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes // N. Engl. J. Med. - 2012. - Vol. 367. - P. 2204-2213.
32. Pool J.L., Schmieder R.E., Azizi M. et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan // Am. J. Hypertens. - 2007. - Vol. 20. - P. 11-20.
33. Pilz B., Shagdarsuren E., Wellner M. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats // Hypertension. - 2005. - Vol. 46. - P. 569-576.
34. Shah S., Coakley C., Hough A. et al. Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension // Ann. Pharmacother. - 2013. - Vol. 47, No. 11. - P. 1562-1568.
35. Schmieder R.E., Philipp T., Guerediaga J. et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren. A 12-month randomized, double-blind comparator trial with hydrochlorothiazide // Circulation. - 2009. - Vol. 119. - P. 417-425.
36. Sechi L.A., Novello M., Colussi G. et al. Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage // Am. J. Hypertens. - 2008. - Vol. 21, No. 12. - P. 1347-1353.
37. Sen S., Sabsrls S., Ozyigit T. et al. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials // Ther. Adv. Chronic Dis. - 2013. - Vol. 4, No. 5. - P. 232-241.
38. Sica D., Gradman A., Lederballe O. et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52-weeks) treatment of hypertension // Eur. Heart J. - 2006. -[Vol.] 27, abstract suppl. - P. 121.
39. Scirica B.M., Morrow D.A., Bode C. et al. Aliskiren in left ventricular hypertrophy (ALLAY) trial investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy // Circulation. - 2009. - Vol. 119. - P. 530-537.
40. Solomon S., Sung H., Shah A. et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with systolic dysfunction // Eur. Heart J. - 2011. - Vol. 32. - P. 1227-1234.
41. Staessen J.A., Li Y., Thijs L. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials // Hypertens. Res. - 2005. -Vol. 28. - P. 385-407.
42. Stanton A. Therapeutic potential of renin inhibition in the management of cardiovascular disorders // Am. J. Cardiovasc. Drugs. - 2003. - Vol. 3. - P. 389-394.
43. Stephan D., Grima M., Welsch M. et al. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the reninangiotensin system // Fundam. Clin. Pharmacol. - 1996. - Vol. 10, No. 5. - P. 474-483.
44. Suzuki H., Okada K., Abe M. et al. Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis // Clin. Exp. Nephrol. - 2013. - Vol. 17, No 3. - P. 386-395.
45. Spence J.D. Physiologic tailoring of treatment in resistant hypertension // Current Cardiology Reviews. - 2010. - Vol. 6. -P. 119-123.
46. Tang S.C., Lin M., Tam S. et al. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study // Nephrol. Dial. Transplant. - 2012. - Vol. 27, No. 2. - P. 613-618.
47. Touyz R.M. Combination antihypertensive treatment with aliskiren and blockers of the Renin-Angiotensin system-reassurance but with a note of caution // Can. J. Cardiol. - 2013. - Vol. 29, No. 5. - P. 521-523.
48. Turnbull F. Effect of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials // Lancet. - 2003. -Vol. 362. - P. 1527-1535.
49. Uresin Y., Taylor A., Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension // J. Renin Angiotensin Aldosterone Syst. - 2007. - Vol. 8. - P. 190-198.
50. Villamil A., Chrysant S., Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide // J. Hypertens. - 2007. - Vol. 25. - P. 217-226.
51. Vaidyanathan S., Warren V., Yeh C. et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment // Clin. Pharmacol. - 2007. - Vol. 47, No. 2. - P. 192-200.
52. Vaidyanathan S., Valencia J., Kemp C. et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochloro-thiazide (HCTZ) and ramipril in healthy volunteers // Int. J. Clin. Pract. - 2006. - Vol. 60. - P. 1343-1356.
53. Watanabe T., Barker T.A., Berk B.C. Angiotensin II and the endothelium: diverse signals and effects // Hypertension. - 2005. - Vol. 45. - P. 163-169.
54. Weir M.R. Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers // Current Hypertensions Reports. - 2002. - Vol. 4. - P. 333-335.
55. Weir M., Bush C., Zhang J. et al. Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis // Eur. Heart J. - 2006. -Vol. 27, abstract suppl. - P. 299.
56. Whaley-Connell A., Nistala R., Habibi J. et al. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat // Am. J. Physiol. Renal Physiol. - 2010. - Vol. 298. - P. 655-661.
57. White W.B., Bresalier R., Kaplan A.P. et al. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: A pooled analysis of clinical experience of 12,942 patients // J. Clin. Hypertens. (Greenwich). - 2010. - Vol. 12, No. 10. - P. 765-775.
58. Woo K.T., Choong H.L., Wong K.S. et al. A retrospective aliskiren and losartan study in non-diabetic chronic kidney disease // World Journal of Nefrology. - 2013. - Vol. 2, No. 4. - P. 129135.
59. Wu M.T., Tung S.C., Hsu K.T. et al. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial [Электронный ресурс] // Journal of the Renin-Angiotensin-Aldosteron System. - 2012. -doi:10.1177/1470320312467560; PMID: 23223162.
60. Yoshitomi Y., Kawanishi K., Yamaguchi A. et al. Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension // Int. Heart J. - 2013. - Vol. 54, No. 2. - P. 88-92.